Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

Read post on prnewswire.com

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...